FTC orders Illumina to divest $7.1 billion acquisition of cancer test developer Grail

FTC orders Illumina to divest $7.1 billion acquisition of cancer test developer Grail

The decision reverses an administrative judge’s ruling that dismissed the FTC’s initial challenge of Illumina’s $7.1 billion Grail deal.

40,111
Like
Save

Comments

Comments are disabled for this post.

Forex SearchClose
Copyright © RichFXM.com. Back to Forex Search